Evidence map›Paper›PMID 34181563›Full record

ArticleJMIR public health and surveillance2021

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.

Elizabeth Pisani, Amalia Hasnida, Mawaddati Rahmi, Maarten Olivier Kok, Steven Harsono, Yusi Anggriani

Open access · goldAbstract read
In one paragraph

Article in JMIR public health and surveillance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Elizabeth PisaniErasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands.ORCID 0000-0002-3674-631X
Amalia HasnidaErasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands.ORCID 0000-0002-9264-334X
Mawaddati RahmiFaculty of Pharmacy, Universitas Pancasila, Jakarta, Indonesia.ORCID 0000-0002-1639-2227
Maarten Olivier KokErasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands.ORCID 0000-0001-8957-1253
Steven HarsonoIQVIA Public Health, Singapore, Singapore.ORCID 0000-0002-3057-203X
Yusi AnggrianiFaculty of Pharmacy, Universitas Pancasila, Jakarta, Indonesia.ORCID 0000-0001-7787-0539
Pancasila University · IDErasmus University Rotterdam · NLVrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country has measured the market-wide extent of the problem, and no standardized methods exist to estimate the prevalence of either substandard or falsified medicines. This is, in part, because the task seems overwhelming; medicine markets are huge and diverse, and testing medicines is expensive. Many countries do operate some form of postmarket surveillance of medicine, but their methods and goals differ. There is currently no clear guidance on which surveillance method is most appropriate to meet specific public health goals. In this viewpoint, we aimed to discuss the utility of both case finding and risk-based sentinel surveillance for substandard and falsified medicines, linking each to specific public health goals. We posit that choosing the system most appropriate to the goal, as well as implementing it with a clear understanding of the factors driving the production and sale of substandard and falsified medicines, will allow for surveillance resources to be concentrated most efficiently. We adapted principles used for disease outbreak responses to suggest a case-finding system that uses secondary data to flag poor-quality medicines, proposing risk-based indicators that differ for substandard and falsified medicines. This system potentially offers a cost-effective way of identifying "cases" for market withdrawal, enhanced oversight, or another immediate response. We further proposed a risk-based sentinel surveillance system that concentrates resources on measuring the prevalence of substandard and falsified medicines in the risk clusters where they are most likely to be found. The sentinel surveillance system provides base data for a transparent, spreadsheet-based model for estimating the national prevalence of substandard and falsified medicines. The methods we proposed are based on ongoing work in Indonesia, a large and diverse middle-income country currently aiming to achieve universal health coverage. Both the case finding and the sentinel surveillance system are designed to be adaptable to other resource-constrained settings.

Indexed as

Counterfeit DrugsCommerceHumansPublic HealthSentinel SurveillanceCounterfeit Drugscounterfeit medicinefalsified medicinemedicine qualitypharmaceuticalspublic healthpublic health surveillancesentinel surveillancesubstandardsubstandard drugssurveillance

Identifiers

PMID34181563
PMCPMC8406122
OpenAlexW3173374615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.